Skip to content
    AME
    Earnings call· Dec 2024(Q4 FY24)

    AMETEK INC/ Q4 FY24 earnings call AME

    Feb 4, 2025 Source

    Executive summary

    AMETEK Q4 FY24 — Record Performance Driven by Operational Excellence and Strong Cash Flow

    AMETEK concluded FY24 with record Q4 performance, showcasing robust operational execution and strong cash generation despite a challenging macro environment. The company's strategic focus on innovation and disciplined capital allocation, including a recent acquisition and share repurchases, positions it for continued growth. While cautious on the near-term outlook, management is encouraged by improving order trends and a strong M&A pipeline.

    Highlights

    5
    • Record sales of $1.76 billion, up 2% from prior year.

    • Record diluted EPS of $1.87, up 11% year-over-year and above guidance.

    • Operating margins expanded by 90 basis points to 26.6%, with core margins up 140 basis points.

    • Record free cash flow of $498 million, up 4% year-over-year, with 129% conversion to net income.

    • Organic orders increased by 4% year-over-year, with positive growth across both EIG and EMG segments.

    Concerns

    4
    • Organic sales declined by 3% in Q4 FY24.

    • EIG experienced temporary project delays due to customer caution at year-end.

    • EMG's OEM-exposed businesses continued to face headwinds from inventory destocking, leading to a 4% organic sales decline.

    • Full-year 2025 sales and EPS guidance reflect a cautious outlook given ongoing macroeconomic uncertainties.

    Guidance & targets

    20
    CategoryTargetConfidence
    Full-year 2025 Overall Sales Growth
    low single digits % increase
    high materiality
    Medium
    Full-year 2025 Organic Sales Growth
    low single digits % increase
    high materiality
    Medium
    Full-year 2025 Diluted EPS
    $7.02 to $7.18
    high materiality
    Medium
    Q1 2025 Overall Sales Growth
    roughly flat
    medium materiality
    Medium
    Q1 2025 Adjusted EPS
    $1.67 to $1.69
    medium materiality
    Medium
    Full-year 2025 Effective Tax Rate
    19% to 20%
    low materiality
    Medium
    Full-year 2025 Capital Expenditures
    approximately $155 million
    medium materiality
    Medium
    Full-year 2025 Depreciation and Amortization
    approximately $400 million
    low materiality
    Medium
    Full-year 2025 Free Cash Flow Conversion
    approximately 115%
    medium materiality
    Medium
    Full-year 2025 General and Administrative Expenses
    approximately 1.5% of sales
    low materiality
    Medium
    Full-year 2025 Other Operating Expenses
    largely in line with 2024 level
    low materiality
    Medium
    Full-year 2025 Incremental Growth Investments
    approximately $85 million
    medium materiality
    Medium
    Full-year 2025 Organic Sales Growth - Process Businesses
    low single digits
    medium materiality
    Medium
    Full-year 2025 Organic Sales Growth - Aerospace & Defense
    mid-single digits
    medium materiality
    Medium
    Full-year 2025 Organic Sales Growth - Power & Industrial
    flat
    medium materiality
    Medium
    Full-year 2025 Organic Sales Growth - Automation & Engineered Solutions
    mid-single digits
    medium materiality
    Medium
    Full-year 2025 Organic Sales Growth - EMG
    slightly higher than EIG
    medium materiality
    Medium
    Paragon MedTech Business Growth
    higher than AMETEK
    medium materiality
    Medium
    Paragon MedTech Margin Improvement
    well in excess of 20 or 30 basis points
    medium materiality
    High
    Price Capture vs. Inflation
    offset increased price with inflation by a little bit
    low materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Electronic Instruments Group (EIG)
    Delivered outstanding performance with impressive margin expansion and record operating margins. Growth was strongest in Aerospace & Defense and advanced optical metrology, but experienced project delays due to customer caution.
    Organic sales: -3%Acquisitions contribution: +1 pointOperating income: $386.6 millionOperating income growth: +8%
    $1.21 billion-2%31.8%
    Electromechanical Group (EMG)
    Finished the year with strong operating performance. Strong performance in Aerospace & Defense was offset by weakness in OEM-exposed businesses due to inventory destocking.
    Organic sales: -4%Operating income: $111.2 millionOperating income growth: -1%
    $546 million20.3%

    Operational metrics

    42
    Operating Margin
    26.6%+90 bps YoY
    Q4 FY24

    Record operating margins for the quarter.

    Core Operating Margin
    up 140 basis points
    Q4 FY24

    Strong core margin expansion.

    EBITDA Margin
    31.9%
    Q4 FY24

    Impressive EBITDA margin for the quarter.

    Free Cash Flow Conversion
    129%
    Q4 FY24

    Robust cash generation.

    Diluted EPS
    $1.87+11% YoY
    Q4 FY24

    Record diluted EPS, above guidance range of $1.81 to $1.86.

    Full-year Operating Margin
    26.1%+20 bps YoY
    FY24

    Full-year operating margin.

    Full-year Core Operating Margin
    up 120 basis points
    FY24

    Full-year core margin expansion.

    Full-year EBITDA Margin
    31.4%
    FY24

    Very strong full-year EBITDA margin.

    Full-year Free Cash Flow Conversion
    124%
    FY24

    Very strong full-year free cash flow conversion.

    Full-year Diluted EPS
    $6.83+7% YoY
    FY24

    Full-year diluted EPS.

    Share Repurchases
    $155 million
    Q4 FY24

    Opportunistic share repurchases.

    Total Share Repurchases
    $220 million
    FY24

    Total share repurchases for the year.

    General and Administrative Expenses
    $28.9 millionup $2.5 million YoY
    Q4 FY24

    In line with 2023 levels as a percentage of sales.

    Full-year General and Administrative Expenses
    up approximately $5 million
    FY24

    In line with 2023 levels as a percentage of sales.

    Other Operating Expenses
    down $1 millionYoY
    Q4 FY24

    Lower due diligence costs contributed to the decrease.

    Effective Tax Rate
    12.8%down from 17.8% YoY
    Q4 FY24

    Lower due to statute expirations.

    Full-year Effective Tax Rate
    17.3%
    FY24

    In line with guidance range of 17% to 17.5%.

    Capital Expenditures
    $52 million
    Q4 FY24

    Capital expenditures for the quarter.

    Full-year Capital Expenditures
    $127 million
    FY24

    Full-year capital expenditures.

    Depreciation and Amortization Expense
    $96 million
    Q4 FY24

    Depreciation and amortization for the quarter.

    Full-year Depreciation and Amortization Expense
    $383 million
    FY24

    Full-year depreciation and amortization.

    Operating Working Capital
    16.8%
    Q4 FY24

    Operating working capital as a percentage of sales.

    Total Debt
    $2.1 billiondown $1.2 billion from YE23
    Year-end 2024

    Total debt at year-end.

    Cash and Cash Equivalents
    $374 million
    Year-end 2024

    Cash balance offsetting total debt.

    Gross Debt-to-EBITDA Ratio
    0.9x
    Year-end 2024

    Leverage ratio at year-end.

    Net Debt-to-EBITDA Ratio
    0.8x
    Year-end 2024

    Leverage ratio at year-end.

    Financial Capacity
    $2.5 billion
    Current

    Excellent financial capacity to support acquisition strategy and growth initiatives.

    Incremental Growth Investments
    $90 million
    FY24

    Investments made to support organic growth initiatives.

    Price Capture
    a bit more than 3%
    FY24

    Price capture for the year.

    Inflation
    a little bit more than 2%
    FY24

    Inflation impact for the year.

    Paragon MedTech Revenue Base
    ~$420 million
    FY24

    Estimated revenue base for the Paragon business.

    Vitality Index
    30%
    Q4 FY24

    Extremely high, at the top end of the target range of 20% to 30%.

    Organic Sales Growth - EIG
    -3%
    Q4 FY24

    Organic sales for EIG.

    Organic Sales Growth - EMG
    -4%
    Q4 FY24

    Organic sales for EMG.

    Organic Sales Growth - Aerospace & Defense
    mid-single digits
    Q4 FY24

    Strongest growth in Q4 was across commercial businesses.

    Organic Sales Growth - Aerospace & Defense
    high-single digits
    FY24

    Strong full-year growth.

    Organic Sales Growth - Process Businesses
    low single digitsdeclined
    Q4 FY24

    Declined in Q4, but with strong growth in advanced optical metrology and high-end microscopy.

    Organic Sales Growth - Power & Industrial
    flat
    Q4 FY24

    Sales were flat, with RTDS business showing growth.

    Organic Sales Growth - Automation & Engineered Solutions
    high single digitsdown
    Q4 FY24

    Consistent with levels seen during the year due to continued OEM customer inventory normalization.

    International Sales Growth
    +2%
    FY24

    Strong growth in Europe and Asia.

    US Sales Growth
    down MST
    FY24

    Primarily due to the automation business.

    China Sales Growth
    roughly flat
    FY24

    China sales were roughly flat for the full year.

    Industry KPIs

    4
    MetricValueDetails
    Book to bill ratio1.01
    Orders bookings growth+4%%
    M a acquisition contribution+5 pointspoints
    Backlog by segment end market$3.4 billionUSD

    Orderbook & backlog

    1
    Total Backlog$3.4 billionQ4 FY24 end

    Product announcements

    1
    ProductTypeDetails
    LEAP 6000 XR Atom Probe microscopelaunch

    Deals & partnerships

    1
    Kern MicrotechnikAcquisition of a leading manufacturer of high-precision machining and optical inspection solutions.approximately EUR 105 million

    Kern is headquartered near Munich, Germany, with annual sales of approximately EUR 50 million. It is a strong strategic fit with AMETEK's Ultra Precision Technologies business, expanding capabilities in submicron level accuracy systems. Management team is staying with AMETEK.

    Risks & headwinds

    4
    Macroeconomic uncertaintiesFY25

    Low single-digit sales growth guidance for FY25, flat Q1 FY25 sales.

    Mitigation: Strong backlog, leading positions in diverse markets, significant capital for strategic acquisitions, flexible operating model.

    OEM inventory destockingOngoing, abating throughout FY25

    EMG organic sales down 4% in Q4 FY24; Automation & Engineered Solutions organic sales down high single digits in Q4 FY24.

    Mitigation: Improved order patterns from some OEM customers, end demand in med tech procedures remains strong, cost structure leaned out in automation business.

    Project delays in EIGQ4 FY24 (temporary), expected to abate in FY25

    EIG organic sales down 3% in Q4 FY24.

    Mitigation: Viewed as temporary, strong new project pipeline, orders were solid.

    Potential tariffs and trade policy changesFY25 and beyond

    Not quantified in guidance, but could impact costs.

    Mitigation: Contingency plans based on 2017-2018 playbook (China for China manufacturing, supply chain decoupling), ability to pass on cost impacts, significant U.S. manufacturing footprint, flexible asset-light model.

    What to watch in Q1 FY25

    5

    Organic Sales Growth - Automation & Engineered Solutions

    throughout FY25
    Currentdown high single digits in Q4 FY24
    Targetimproving growth trends

    Why it matters

    This segment was heavily impacted by OEM destocking; its recovery is key to EMG's overall performance and the company's organic growth acceleration.

    And for 2025, we expect organic sales to be up mid-single digits for the year with improving growth trends throughout the year.

    Q&A highlights

    6

    Can you elaborate on the nature of EIG project delays and if they are resolving? Also, what is the expected duration of OEM destocking impacting EMG?

    EIG project delays are typical and temporary, with a strong new project pipeline. OEM destocking in EMG is easing, with some customers through it and others still working through inventory. Sequential order growth in Paragon (double-digit) and overall EIG orders are positive, continuing into January.

    The project delays in EIG were pretty much what we've been seeing. It was across the board. It wasn't really notable, but we got some delays on the shipments, but the orders were good. And similar, the destocking headwinds largely impacted our OEM exposed businesses in EMG which include our Automation & Engineered Solutions subsegment. But we're starting to see improved order patterns from some OEM customers, while others are taking a little time to destock.

    asked by Matt Summerville · answered by David Zapico

    2 min read6 chapters

    Detailed Narrative

    01

    Operational Excellence Driving Record Results

    AMETEK achieved record sales, operating income, EBITDA, and diluted EPS in Q4 FY24, demonstrating the effectiveness of its operating model. Operating margins expanded by 90 basis points to 26.6%, with core margins up 140 basis points, reflecting strong productivity, positive price/cost dynamics, and favorable mix. This consistent margin performance is attributed to the company's DNA of operational excellence and high contribution margin businesses.

    02

    Capital Deployment Strategy and M&A Pipeline

    The company repurchased $155 million in shares during Q4, bringing the FY24 total to $220 million, while maintaining acquisitions as its top capital deployment priority. Subsequent to the quarter, AMETEK acquired Kern Microtechnik for approximately EUR 105 million, a strategic fit for its Ultra Precision Technologies business. Management highlighted a strong pipeline of high-quality acquisition candidates and significant financial capacity, with the ability to deploy up to $5 billion in 2025 while maintaining a healthy debt-to-EBITDA ratio.

    03

    Strategic Investments in Growth and Innovation

    AMETEK invested approximately $90 million in incremental growth initiatives in FY24, primarily in research, development, and engineering (RD&E) and sales & marketing. A similar investment of $85 million is planned for FY25, with about two-thirds allocated to RD&E. These investments have strengthened leadership positions, opened new growth opportunities, and accelerated new product development, as exemplified by the LEAP 6000 XR Atom Probe microscope, which enhances productivity and broadens market reach.

    04

    Segment Performance and Market Dynamics

    EIG delivered outstanding performance with record operating income and margins, despite project delays. EMG faced headwinds from OEM destocking, particularly in Automation & Engineered Solutions, but saw improved order patterns. Aerospace & Defense businesses showed strong growth, with commercial OE sales increasing. Management expects EMG's organic growth to be slightly higher than EIG's in FY25, driven by the abatement of destocking and strong pipelines.

    05

    Geographic Trends and Macroeconomic Outlook

    In FY24, AMETEK experienced strong growth in Europe and Asia, offset by declines in the U.S., primarily due to the automation business. For FY25, the company anticipates balanced growth across all geographies, with continued strength in Europe and Asia (especially outside China) and a return to growth in the U.S. Management remains cautious about macroeconomic uncertainties but is encouraged by improving order trends and a strong backlog, not assuming broader economic slowdown from potential trade wars.

    06

    Tariff Preparedness and Operational Agility

    AMETEK has contingency plans for potential tariffs, leveraging its 2017-2018 playbook of decoupling supply chains from China and its significant U.S. manufacturing footprint. The company expects to pass on cost impacts to customers if tariffs are enacted, given its niche, highly-differentiated products. This flexible, asset-light model positions AMETEK to manage through potential trade policy changes without assuming demand destruction in its guidance.

    AI-generated summary of the company’s earnings call. Not investment advice.